The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
While admittedly, I am not an active poster here (partly because this stock has been a slow burn for over a year compared to vaccine stocks with their daily twists and turns, partly because I invest mostly in US biotech stocks, and partly b/c I would rather read others' opinions and only post if seeking feedback), being called a closet deramper is a first. Getting into petty arguments is really not my thing.
Thanks Doc
oh give up boy and girls . Classic team tag de-ramp on the whole thread.
Thank you Ndn, I hadn't thought of it that way. I only focused on the endpoints but there is always data to be gleaned.
Ndn
Well summarised
Its a good point Mopod. The most likely scenario, with the new diagnostics being developed, is that covid positive patients with IFN autoantibodies or those with IFN genetic deficiencies will be treated at home early in disease.
The home trial was a proof of concept that could prove very valuable down the line.
modpod, I was not precise enough and I agree.
With regards to your second point - intervening in someone who is ‘high risk’ yet may have ‘mild flu symptoms’ is really relevant to the stage of their infection. Target infection here and reduce the risk of multi system involvement which requires more intervention, more money and more inpatient care.
Do you treat every patient with ‘mild flu symptoms’, No. Do you make a calculated assessment of poor outcomes in those with known co-mobidities, yes.
Symptoms do not equal outcomes.
Telling someone to "buzz off" is not considered aggressive? You must really struggle to negotiate civilized society.
1. From what I have read, I believe SNG mgt have done their part. However, one HAS to ask and seek other investors' views. That was the point of my post.
2. Atea's mistake is a similar mistake to the one SNG made when pursuing the home trial, in my opinion. I am very pleased of course that we have made it past P2 of Active-2. However, my belief is that SNG distinguishes itself in helping those with acute symptoms. I am surprised you are so upset at what is supported by results and common sense...why spend £1400 on someone with mild flu-like symptoms? My point in posting this was to see if others had simialr views or disagreed.
As for my level of investment - disclosing my exposure was a knee jerk reaction and isn't relevant. Whether I hold 100 shares or 100K shares, the points still hold.
Thanks for your thoughts Kevin
No aggression whatsoever from me.
I doubt it, looking at your posts.
If I’m wrong, of course, good luck to you!
Kevin, I have no idea where your aggressive comment is coming from. Both are things that investors must factor in.
For the record, I have 35,000 shares.
Jimmy
You clearly have no shares in SNG, buzz off.
I think this is what oak was referring to?
1. From Novavax - don't underestimate the complexity of manufacturing . I truly hope that it is far easier to manufacture nebulisers than vaccines
2. From Atea - the wrong patient target for a good drug can be deadly for a company. We learned this through the home trial and hopefully SPRINTER will provide clear evidence and put an end to questions of effectiveness.